Vertex Pharmaceuticals
VRTX
Market cap $126B

489.10 USD

+3.21

0.66%

At close Apr 17, 4:00 PM EDT

After hours

489.10

+0.00

0.00%

1 day

0.66%

5 days

2.51%

1 month

-4.80%

3 months

15.90%

6 months

-1.93%

Year to date

20.54%

1 year

24.42%

5 years

80.84%

10 years

291.06%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 192 | Existing positions closed: 153

11% more call options, than puts

Call options by funds: $780M | Put options by funds: $700M

2.03% more ownership

Funds ownership: 89.52% [Q3] → 91.54% (+2.03%) [Q4]

0% more funds holding

Funds holding: 1,526 [Q3] → 1,529 (+3) [Q4]

10% less repeat investments, than reductions

Existing positions increased: 546 | Existing positions reduced: 604

11% less capital invested

Capital invested by funds: $107B [Q3] → $95.5B (-$11.8B) [Q4]

45% less funds holding in top 10

Funds holding in top 10: 29 [Q3] → 16 (-13) [Q4]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$420

14%

downside

Avg. target

$485

1%

downside

High target

$567

16%

upside

11 analyst ratings

5 positive

45%

6 neutral

55%

0 negative

0%

RBC Capital Brian Abrahams 3% 1-year accuracy 2 / 66 met price target	14%downside $420	Sector Perform Maintained	1 Apr 2025
B of A Securities Ying Huang 100% 1-year accuracy 3 / 3 met price target	16%upside $567	Buy Maintained	31 Mar 2025
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 11 / 44 met price target	13%downside $424	Hold Upgraded	12 Feb 2025
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target	6%upside $520	Buy Maintained	11 Feb 2025
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target	8%downside $450	Sector Perform Maintained	11 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 31 articles about VRTX published over the past 30 days

The Motley Fool

Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded tariffs on imported goods from most countries for 90 days.

Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next

The Motley Fool

Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce

Yo-yos are fun for kids. But yo-yo stock markets aren't so fun for grown-up investors.

Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce

The Motley Fool

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades

"May you live in interesting times."

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.” Negulescu shares the award with Michae.

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

CNBC Television

Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike

The Investment Committee give you their top stocks to watch in this volatile markets.

Final Trades: Vertex, Robinhood, Palo Alto and Crowdstrike

GreensKeeper Q1 2025 Portfolio Update

Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fueled by its CF franchise and new therapies, Alyftrek and Journavx, with potential blockbuster status for the latter. Alphabet Inc. was the biggest laggard at -18.3%, impacted by increased capital expenditures and a $32 billion acquisition, despite strong operating profits and cash reserves.

GreensKeeper Q1 2025 Portfolio Update

The Motley Fool

We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.

Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs. Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims that Buffett applauded President Trump's economic policies.

We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.

Zacks Investment Research

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

The Motley Fool

5 Top Growth Stocks to Buy in the Stock Market Sell-Off

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells us that equities tend to experience strong runs following downturns, so it's worth putting money into excellent companies that are being dragged down with along with the broader market.

5 Top Growth Stocks to Buy in the Stock Market Sell-Off

The Motley Fool

Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.75%). Compared to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date.

Is Vertex Pharmaceuticals Stock a Buy?

See News Rankings

Charts implemented using Lightweight Charts™